Apyx Medical - APYX Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APYX shares.
View APYX analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12 month price objectives for Apyx Medical's shares. Their APYX share price forecasts range from $3.00 to $10.00. On average, they expect the company's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 321.2% from the stock's current price.
View analysts price targets for APYX or view top-rated stocks among Wall Street analysts.

Apyx Medical's stock was trading at $12.82 at the beginning of the year. Since then, APYX stock has decreased by 85.8% and is now trading at $1.82.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our APYX earnings forecast.

Apyx Medical Co. (NASDAQ:APYX) issued its earnings results on Thursday, November, 10th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.05. The business earned $9.11 million during the quarter, compared to analyst estimates of $12 million. Apyx Medical had a negative net margin of 39.28% and a negative trailing twelve-month return on equity of 39.82%.

Apyx Medical issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $44.80 million-$47.90 million, compared to the consensus revenue estimate of $53.47 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), ONEOK (OKE), Occidental Petroleum (OXY), Procter & Gamble (PG), STORE Capital (STOR), Wells Fargo & Company (WFC), Boeing (BA), Bank of America (BAC) and Delta Air Lines (DAL).

Apyx Medical trades on the NASDAQ under the ticker symbol "APYX."

Apyx Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Pura Vida Investments LLC (4.36%), Vanguard Group Inc. (4.09%), Kent Lake Capital LLC (3.03%), Invenire Partners LP (2.74%), UBS Group AG (2.57%) and Royce & Associates LP (2.56%).
View institutional ownership trends.

Shares of APYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APYX stock can currently be purchased for approximately $1.82.

Apyx Medical (NASDAQ:APYX) has a market capitalization of $62.97 million and generates $48.52 million in revenue each year. The company earns $-15,170,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

The company employs 272 workers across the globe.

Apyx Medical's mailing address is 5115 Ulmerton Road, Clearwater FL, 33760. The official website for the company is www.apyxmedical.com. The company can be reached via phone at (727) 384-2323, via email at investor.relations@apyxmedical.com, or via fax at 800-323-1640.